Royalty Pharma PLC
F:RPD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Royalty Pharma PLC (RPD) under the Base Case is 37.55 EUR per share.
Compared with the current market price of 58.64 EUR, the stock appears
Overvalued by 36% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Royalty Pharma Does
Royalty Pharma is not a drugmaker. It buys rights to a slice of future sales from medicines developed by other companies, then collects royalty payments when those drugs are sold. In practice, it gives biotech and pharmaceutical firms upfront cash in exchange for a share of revenue from approved drugs or late-stage drug programs.
- Headquarters
- United States of America US
- Employees
- 100
- IPO date
- Jun 16, 2020
Royalty Pharma has a narrow economic moat
Lower funding costs let Royalty Pharma offer drug developers attractive financing while still earning a profit. It also receives a share of sales from medicines whose patents and exclusive selling rights limit competition from cheaper copies.
Read the full moat analysis
Earnings Waterfall
Royalty Pharma PLC
What is the Intrinsic Value of one RPD stock?
The intrinsic value for Royalty Pharma PLC (RPD) under the Base Case is 37.55 EUR.
Is RPD stock undervalued or overvalued?
Compared with the current market price of 58.64 EUR, the stock appears Overvalued by 36% .
